I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO Asia 2024

-
Coming soon
09:15 AM
Duration 5mins Hall 406
ALESIA 7-year update: alectinib vs crizotinib in Asian patients with treatment-naïve advanced ALK+ non-small cell lung cancer
Zhou C, Lu Y, Kim S-W, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang J-J, Cheng Y, Lee S-H, Chang J, Fang J, Liu Z, Bu L, Qian L, Archer V, Zhou M, Zhang L

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:50 AM
Duration 55mins Singapore, Republic of Singapore
Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo)
Steven Kao, Martin Reck, Stephen V. Liu, Rafal Dziadziuszko, Maximilian Hochmair, Florian Huemer, Gilberto Castro, Junior, Reyes Bernab Caro, Se Hyun Kim, Dariusz Kowalski, Zoran Andric, Marcela Oancea, Monika Kaul, Huafei Li, Bradford Danner, Myung Chang Lee, Barzin Nabet, Shunichi Sugawara

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 55mins Singapore, Republic of Singapore
Patient satisfaction and preference for atezolizumab subcutaneous by body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002
Chewaskulyong B, Zvirbule Z, Lee KH, Yovanna Castro Sanchez A, Bustillos A, Herraez-Baranda L, Liu LX, Kim S-W

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 55mins Singapore, Republic of Singapore
Resistance mechanisms and efficacy of first-line (1L) alectinib in patients with ALK-rearranged non-small cell lung cancer: second interim analysis of ALCURE
Atsuto Mouri, Takeshi Tsuda, Masahide Oki, Eiki Ichihara, Hiroshi Tanaka, Koichi Azuma, Ryo Arai, Shoichi Kuyama, Hiroaki Akamatsu, Kohei Otsubo, Hitomi Ajimizu, Marie Matsumoto, Yosuke Seto, Ken Uchibori, Hidetoshi Hayashi, Eisaku Miyauchi, Naoki Ishizuka, Yusuke Kajihara, Yuki Nakagawa, Ryohei Katayama

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 55mins Singapore, Republic of Singapore
SKYSCRAPER-02C: phase 3 study of atezolizumab + carboplatin + etoposide (CE) with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in China
Shun Lu, Jian Fang, Yan Yu, Yun Fan, Xiaorong Dong, Haiyan Wang, Chanjuan Lin, Li Zhang, Raymond Meng

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar